Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
This antibody is specific for hepatic proliferating duct cells.
Facultative liver stem cell activation was originally described in the rat, where chemical damage and partial hepatectomy caused the emergence of a new cell type, the oval cell. These cells are thought to be bipotential progenitors capable of yielding both hepatocytes and bile ducts. To properly determine the molecular regulation of the progenitor process, appropriate markers are needed to identify and isolate cells that emerge during the oval cell response.
仅用于科研。不用于诊断过程。未经明确授权不得转售。